CN108430514B - 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法 - Google Patents

用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法 Download PDF

Info

Publication number
CN108430514B
CN108430514B CN201680073817.9A CN201680073817A CN108430514B CN 108430514 B CN108430514 B CN 108430514B CN 201680073817 A CN201680073817 A CN 201680073817A CN 108430514 B CN108430514 B CN 108430514B
Authority
CN
China
Prior art keywords
dendrimer
leukodystrophy
disease
peroxisome
leukoencephalopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680073817.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108430514A (zh
Inventor
S·卡纳安
K·兰格拉曼奴贾姆
张帆
S·A·法塔米
B·特克
O·葛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Kennedy Krieger Institute Inc
Original Assignee
Johns Hopkins University
Kennedy Krieger Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Kennedy Krieger Institute Inc filed Critical Johns Hopkins University
Publication of CN108430514A publication Critical patent/CN108430514A/zh
Application granted granted Critical
Publication of CN108430514B publication Critical patent/CN108430514B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680073817.9A 2015-10-29 2016-10-31 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法 Active CN108430514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248163P 2015-10-29 2015-10-29
US62/248,163 2015-10-29
PCT/US2016/059697 WO2017075580A1 (en) 2015-10-29 2016-10-31 Compositions and methods for treatment of peroxisomal disorders and leukodystrophies

Publications (2)

Publication Number Publication Date
CN108430514A CN108430514A (zh) 2018-08-21
CN108430514B true CN108430514B (zh) 2023-11-03

Family

ID=57233968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073817.9A Active CN108430514B (zh) 2015-10-29 2016-10-31 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法

Country Status (7)

Country Link
US (2) US20170119899A1 (https=)
EP (1) EP3368088B1 (https=)
JP (2) JP7088473B2 (https=)
CN (1) CN108430514B (https=)
AU (1) AU2016343855B2 (https=)
CA (1) CA3003589C (https=)
WO (1) WO2017075580A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342575B2 (ja) * 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2019118951A2 (en) * 2017-12-15 2019-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
WO2020081923A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2020142373A1 (en) * 2019-01-02 2020-07-09 Mayo Foundation For Medical Education And Research Methods and materials for treating leukodystrophies
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
PH12022552818A1 (en) * 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
US20230364244A1 (en) * 2020-07-17 2023-11-16 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to injured kidney
WO2023081750A1 (en) * 2021-11-04 2023-05-11 The Children's Hospital Of Philadelphia Compositions and methods for treating metachromatic leukodystrophy disease and related disorders
WO2024081687A2 (en) * 2022-10-12 2024-04-18 The Johns Hopkins University Method of treating lbsl by enhancing dars2 expression
CN116082153A (zh) * 2022-12-09 2023-05-09 长沙贝塔医药科技有限公司 一种丙烯酸酯类衍生物-13c的制备方法
EP4410284A1 (en) * 2023-02-02 2024-08-07 Apteeus Compound and method for the treatment of zellweger spectrum disorder
CN117643581A (zh) * 2023-11-29 2024-03-05 徐州医科大学 白藜芦醇在制备激活sirt1基因的药物中的应用
WO2025240286A1 (en) * 2024-05-14 2025-11-20 Washington State University Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495152A (zh) * 2006-05-22 2009-07-29 艾伦药物公司 通过三信反应制备作为vla-4拮抗剂的聚合物结合物的方法
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69612755T2 (de) 1995-02-07 2001-08-23 Brusilow Enterprises, Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
AU6269799A (en) * 1998-09-28 2000-04-17 Johns Hopkins University, The Adrenoleukodystrophy treatments and drug screening
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
PL2214646T3 (pl) * 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
EP2596112A4 (en) 2010-07-21 2015-01-21 Cumberland Pharmaceuticals Inc ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
CN105813690A (zh) 2013-08-21 2016-07-27 协和大学 树状聚合物-白藜芦醇复合物
CN106659798A (zh) * 2014-08-13 2017-05-10 约翰霍普金斯大学 树枝状聚合物组合物和在治疗神经与cns病症中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495152A (zh) * 2006-05-22 2009-07-29 艾伦药物公司 通过三信反应制备作为vla-4拮抗剂的聚合物结合物的方法
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dendrimer Brain Uptake and Targeted Therapy for Brain Injury in a Large Animal Model of Hypothermic Circulatory Arrest;Manoj K. Mishra et al.;《ACSNANO》;20140325;第8卷(第3期);摘要和Figure 3，第2140页Preparation of Dendrimer-NAC Conjugate (D-NAC, 5) *
Pathophysiology of X-linked adrenoleukodystrophy;J.Berger et al.;《Biochimie》;20131204;第98卷;第139页4. Functional redundancy of ABC transporters and their role in the pathophysiology of X-ALD和6. Pathophysiology of inflammation in cerebral X-ALD *

Also Published As

Publication number Publication date
AU2016343855A1 (en) 2018-05-10
JP2018531965A (ja) 2018-11-01
US20170119899A1 (en) 2017-05-04
AU2016343855B2 (en) 2019-10-03
CA3003589A1 (en) 2017-05-04
JP7088473B2 (ja) 2022-06-21
JP2022105767A (ja) 2022-07-14
CA3003589C (en) 2021-12-07
EP3368088A1 (en) 2018-09-05
WO2017075580A1 (en) 2017-05-04
CN108430514A (zh) 2018-08-21
US20220071923A1 (en) 2022-03-10
EP3368088C0 (en) 2023-06-07
EP3368088B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CN108430514B (zh) 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
An et al. Applications of nanomaterials for scavenging reactive oxygen species in the treatment of central nervous system diseases
JP6531164B2 (ja) 神経障害およびｃｎｓ障害の処置におけるデンドリマー組成物および使用
Haroon et al. Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury
ES2640777T3 (es) Terapia anaplerótica para la enfermedad de Alzheimer
US20220080056A1 (en) Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
Zhou et al. ROS/electro dual-reactive nanogel for targeting epileptic foci to remodel aberrant circuits and inflammatory microenvironment
Fu et al. Value of functionalized superparamagnetic iron oxide nanoparticles in the diagnosis and treatment of acute temporal lobe epilepsy on MRI
JP2022541582A (ja) 自己免疫障害を処置するための組成物および方法
AU2015301575A1 (en) Selective dendrimer delivery to brain tumors
Zhang et al. An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel disease
JP2017517528A (ja) 神経疾患および大脳損傷の処置のための組成物および方法
Boussadia et al. Effect of status epilepticus and antiepileptic drugs on CYP2E1 brain expression
CN119053344A (zh) 用于靶向递送治疗剂至神经元的树枝状聚合物组合物
CA3189682A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
Shin et al. Ceruloplasmin is an endogenous protectant against kainate neurotoxicity
Wang et al. Mitochondria-targeting Cu2-xSe-TPP with dual enzyme activity alleviates Alzheimer's disease by modulating oxidative stress
Das et al. Advancement on nanoparticles-based approaches for the management of rheumatoid arthritis (RA): molecular mechanism, toxicity, and clinical perspectives
Mwema et al. Impact of calcitriol and PGD2-G-loaded lipid nanocapsules on oligodendrocyte progenitor cell differentiation and remyelination
Liu et al. YTHDF1-targeting nanoassembly reverses tumoral immune evasion through epigenetics and cell cycle modulation
EP4640227A1 (en) Composition for maintaining or improving immune function
Machtoub et al. Amyotrophic Lateral Sclerosis: Advances and Perspectives of Neuronanomedicine
McCue et al. Examining tissue-level changes in doxorubicin accumulation and nitric oxide formation in skeletal muscle and tumours in a mouse model of breast cancer
Xi et al. Callicarpa nudiflora-derived extracellular vesicle-like particles loaded with budesonide enhance the treatment of ulcerative colitis by regulating M1/M2 macrophage polarization
He et al. ROS-responsive glucosylated nanodisc prodrug for efficient targeted epilepsy therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant